BUND FINANCE › Stocks › ABT
Abbott Laboratories (ABT)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +0.11% above its 50-day average.
- It is +2.43% above its 200-day average (long-term uptrend).
- It sits at 46% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$43.1B | US$43.7B | US$40.1B | US$42.0B | US$44.3B |
| Net income | US$7.1B | US$6.9B | US$5.7B | US$13.4B | US$6.5B |
| EPS (diluted) | 3.94 | 3.91 | 3.27 | 7.64 | 3.72 |
| Gross margin | 53.9% | 51.1% | 50.0% | 50.8% | 55.5% |
| Operating margin | 21.4% | 19.2% | 16.0% | 16.3% | 18.2% |
| Net margin | 16.4% | 15.9% | 14.3% | 32.0% | 14.7% |
| Free cash flow | US$8.6B | US$7.8B | US$5.1B | US$6.4B | US$7.4B |
| Total debt | US$19.3B | US$17.9B | US$15.9B | US$15.3B | US$15.1B |
| Cash | US$9.8B | US$9.9B | US$6.9B | US$7.6B | US$8.5B |
Compound annual growth: revenue 0.7% · net income -2.0% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 38.5x | 29.0x | 26.4x |
| EV / EBITDA | 18.7x | 19.0x | 16.3x |
| Operating margin | 15.0% | — | 3.6% |
| Net margin | 9.8% | — | -0.0% |
| Debt / equity | 1.11 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dysl…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice